These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25444872)

  • 1. siRNAs encapsulated in recombinant capsid protein derived from Dengue serotype 2 virus inhibits the four serotypes of the virus and proliferation of cancer cells.
    Kumar AS; Reddy GE; Rajmane Y; Nair S; Pai Kamath S; Sreejesh G; Basha K; Chile S; Ray K; Nelly V; Khadpe N; Kasturi R; Ramana V
    J Biotechnol; 2015 Jan; 193():23-33. PubMed ID: 25444872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel inhibitor of dengue virus replication that targets the capsid protein.
    Byrd CM; Dai D; Grosenbach DW; Berhanu A; Jones KF; Cardwell KB; Schneider C; Wineinger KA; Page JM; Harver C; Stavale E; Tyavanagimatt S; Stone MA; Bartenschlager R; Scaturro P; Hruby DE; Jordan R
    Antimicrob Agents Chemother; 2013 Jan; 57(1):15-25. PubMed ID: 23070172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recombinant envelope glycoprotein domain III of dengue virus inhibit virus infection].
    Lu P; Wei Y; Cao SC; Li JD; Liu QZ; Zhang QF; Li C; Miao F; Zhang S; Hang XT; Liang MF; Li DX
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Jun; 22(3):177-9. PubMed ID: 19031695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus.
    Suzarte E; Marcos E; Gil L; Valdés I; Lazo L; Ramos Y; Pérez Y; Falcón V; Romero Y; Guzmán MG; González S; Kourí J; Guillén G; Hermida L
    Arch Virol; 2014 Jul; 159(7):1629-40. PubMed ID: 24420159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsid-targeted viral inactivation can destroy dengue 2 virus from within in vitro.
    Qin CF; Qin ED
    Arch Virol; 2006 Feb; 151(2):379-85. PubMed ID: 16155726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo.
    Choi KM; Kim K; Kwon IC; Kim IS; Ahn HJ
    Mol Pharm; 2013 Jan; 10(1):18-25. PubMed ID: 22663765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus.
    Lazo L; Hermida L; Zulueta A; Sánchez J; López C; Silva R; Guillén G; Guzmán MG
    Vaccine; 2007 Jan; 25(6):1064-70. PubMed ID: 17097199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of dengue 2 virus capsid protein and staphylococcal nuclease fusion protein on dengue-infected cell cultures.
    Qin CF; Qin E; Yu M; Chen SP; Jiang T; Deng YQ; Duan HY; Zhao H
    Arch Virol; 2005 Apr; 150(4):659-69. PubMed ID: 15592886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli.
    Jaiswal S; Khanna N; Swaminathan S
    Protein Expr Purif; 2004 Jan; 33(1):80-91. PubMed ID: 14680965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue virus capsid protein usurps lipid droplets for viral particle formation.
    Samsa MM; Mondotte JA; Iglesias NG; Assunção-Miranda I; Barbosa-Lima G; Da Poian AT; Bozza PT; Gamarnik AV
    PLoS Pathog; 2009 Oct; 5(10):e1000632. PubMed ID: 19851456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of target mRNA cleavage by aurorakinase B specific siRNA in prostate and hepatic cancer cells and its therapeutic potential in mouse models of liver cancer.
    Chile SA; Ray KB; Shaikh S; Rajagopal V; Rao HS; Ramana V; Kumar AS
    Indian J Exp Biol; 2014 Oct; 52(10):943-51. PubMed ID: 25345243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized sequential purification protocol for in vivo site-specific biotinylated full-length dengue virus capsid protein.
    Chong MK; Parthasarathy K; Yeo HY; Ng ML
    Protein Eng Des Sel; 2013 May; 26(5):377-87. PubMed ID: 23479673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice.
    Valdés I; Bernardo L; Gil L; Pavón A; Lazo L; López C; Romero Y; Menendez I; Falcón V; Betancourt L; Martín J; Chinea G; Silva R; Guzmán MG; Guillén G; Hermida L
    Virology; 2009 Nov; 394(2):249-58. PubMed ID: 19783271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the mode of action of a potent dengue virus capsid inhibitor.
    Scaturro P; Trist IM; Paul D; Kumar A; Acosta EG; Byrd CM; Jordan R; Brancale A; Bartenschlager R
    J Virol; 2014 Oct; 88(19):11540-55. PubMed ID: 25056895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.
    Izquierdo A; García A; Lazo L; Gil L; Marcos E; Alvarez M; Valdés I; Hermida L; Guillén G; Guzmán MG
    Arch Virol; 2014 Oct; 159(10):2597-604. PubMed ID: 24841761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinome siRNA screen identifies novel cell-type specific dengue host target genes.
    Kwon YJ; Heo J; Wong HE; Cruz DJ; Velumani S; da Silva CT; Mosimann AL; Duarte Dos Santos CN; Freitas-Junior LH; Fink K
    Antiviral Res; 2014 Oct; 110():20-30. PubMed ID: 25046486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of cell lines stably expressing staphylococcal nuclease fused to dengue 2 virus capsid protein for CTVI.
    Qin CF; Qin ED
    Acta Biochim Biophys Sin (Shanghai); 2004 Aug; 36(8):577-82. PubMed ID: 15295652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral activity of lanatoside C against dengue virus infection.
    Cheung YY; Chen KC; Chen H; Seng EK; Chu JJ
    Antiviral Res; 2014 Nov; 111():93-9. PubMed ID: 25251726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Narasin, a novel antiviral compound that blocks dengue virus protein expression.
    Low JS; Wu KX; Chen KC; Ng MM; Chu JJ
    Antivir Ther; 2011; 16(8):1203-18. PubMed ID: 22155902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A custom-designed recombinant multiepitope protein as a dengue diagnostic reagent.
    AnandaRao R; Swaminathan S; Fernando S; Jana AM; Khanna N
    Protein Expr Purif; 2005 May; 41(1):136-47. PubMed ID: 15802231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.